GlassScriptPhysician profile
Luan L Brown
NPI 1811439490
$6,024.12
in general payments reported to CMS, 2019-2025
27 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,027 · 2022: $638 · 2023: $1,204 · 2024: $1,567 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,185 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,184.63 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,497.92 | 2021-2025 | |
| Janssen Biotech, INC. | $855.50 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $740.34 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Aimmune Therapeutics, INC. | $489.27 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $373.91 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $319.36 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $279.75 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $271.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.60 | 2021-2025 | Entyvio |
| Celgene Corporation | $191.12 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $164.03 | 2023-2024 | Stelara |
| Pfizer INC. | $118.21 | 2021 | |
| Lilly USA, LLC | $69.58 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $52.14 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $47.85 | 2024-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $47.73 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $35.53 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $34.99 | 2025 | Iqirvo |
| Novo Nordisk INC | $34.81 | 2025 | Saxenda, Wegovy |
| Gilead Sciences, INC. | $34.69 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $31.10 | 2021 | |
| Organon LLC | $30.53 | 2023-2024 | Hadlima |
| Celltrion USA INC. | $20.52 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $20.17 | 2022 | |
| Enterra Medical, INC. | $20.03 | 2023 | |
| Redhill Biopharma INC. | $15.54 | 2022 | |
| Madrigal Pharmaceuticals | $13.77 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.